Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors - 2017
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors - 2016
Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator - 2016
Pharmacological Targeting of Kinases MST1 and MST2 Augments Tissue Repair and Regeneration - 2016
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer - 2013
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors - 2010
Targeting cancer with small molecule kinase inhibitors - 2009
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M - 2009
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity - 2007
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics - 2007
Publications
_______

Drs. Yun and Zhang, scientific co-founders of RedCloud Bio,

have collaborated with each other for more than fifteen years. Together,

they have significantly contributed to the discovery of many important new d

rug candidates covering multiple cancer types: e.g., non-small cell lung cancer (WZ4002 and EAI045), hematologic (GNF-2, further developed to Asciminib) and solid tumors (BRK inhibitors). Their findings have been described in more than 200 publications in leading journals including Nature, Science, Cell and others.

Publications
Your ability to access these articles may depend on your or your institution's subscriptions to the journals.
Contact Us

 

Nanjing   ｜307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District Shanghai｜Suite 901, 880 Xiangyang Road, Minhang District Beijing   ｜Suite 205, Building No.2, PKUCare Industrial Park, Changping District Website: https://www.redcloudbio.com

Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved